Advertisement

Topics

[News] Savolitinib for -driven papillary renal cell carcinoma

21:54 EDT 29 Jun 2017 | The Lancet

Patients with advanced papillary renal cell carcinoma harbouring MET alterations could respond to treatment with the selective MET tyrosine kinase inhibitor savolitinib, according to the results of a recent clinical trial.

Original Article: [News] Savolitinib for -driven papillary renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "[News] Savolitinib for -driven papillary renal cell carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...